BMO Capital重申了其优于大市的评级，Piper Sandler维持增持评级，Needham尽管将其股票目标价从205美元略微下调至202美元，但仍保持买入评级。Morgan Stanley和Mizuho都重申了200美元的目标价。

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...

11月26日宣布的Sarepta与Arrowhead Pharmaceuticals (NASDAQ:ARWR)的最新合作关系重新引发了投资者的浓厚兴趣。消息公布后，Sarepta股价在收盘时上涨了14%。这笔交易被视为一个积极举措，解决了人们对近期催化剂和长期可持续增长的担忧。

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...

On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading today, for the December 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...